Literature DB >> 34593692

COVID-19 Vaccination Manifesting as Unilateral Lymphadenopathies Detected by 18F-Choline PET/CT.

Domenico Albano1, Giulia Volpi2, Francesco Dondi1, Raffaele Giubbini1, Francesco Bertagna1.   

Abstract

ABSTRACT: A 79-year-old man with a history of prostate adenocarcinoma treated with prostatectomy underwent 18F-FCH PET/CT for restaging purpose, which was negative for relapse but showed the presence of choline-positive lymph nodes in the left axilla. The patient underwent a COVID-19 vaccination in the left arm 6 days prior. Thus, PET/CT findings were considered as inflammatory lymph nodes. With the current drive of global COVID-19 immunization, this case underlines the importance of knowing vaccination history to interpret correctly the findings and to avoid false-positive reports.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34593692      PMCID: PMC8745941          DOI: 10.1097/RLU.0000000000003951

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


A 79-year-old man with a history of prostate adenocarcinoma (Gleason score 4 + 5) treated with prostatectomy underwent a 18F-fluorocholine (18F-FCH) PET/CT for restaging purpose after the increase of prostate-specific antigen (PSA) level (last PSA 1.57 ng/mL; PSA velocity 0.09 ng/mL per month; PSA doubling time 7.8 months). Tracer injection was done via the left antecubital vein. 18F-FCH PET/CT maximum intensity projection (MIP, anterior view, A) demonstrated no increased uptake corresponding to relapse or localization of disease. However, several moderate uptakes in the lest axillary fossa were noted (lateral view, B, black arrows). Axial CT (A, D, G), PET (B, E, H), and PET/CT fused images (C, F, I) confirmed the presence of several axillary nodes both superficial and wide with increased uptake. CT appearance of lymph nodes was suspected for inflammatory nature. This patient received the Oxford-AstraZeneca COVID-19 vaccination in the left upper arm 6 days before PET/CT scan and reported only faint left arm pain. Large-scale worldwide COVID-19 vaccination programs are being rapidly deployed starting from health workers and old frail people. Several articles[1-6] reported increased 18F-FDG uptakes in axillary and subpectoral lymph nodes and deltoid muscle at the same side of the vaccine administration. These findings were interpreted as reactive response due to immune effect after recent vaccination against COVID-19. Also with DOTA peptides, some cases are described.[7-9] Instead, only 1 case of increased radiolabeled choline uptake after vaccination against COVID-19 was described.[10] Our case highlights the possibility to have incidental choline uptake in the axillary nodes after vaccination and underlines the need to pay attention to this finding to avoid incorrect image interpretation and inadvertent upstaging of disease.
  10 in total

1.  COVID-19 Vaccination Manifesting as Incidental Lymph Nodal Uptake on 18F-FDG PET/CT.

Authors:  Najeeb Ahmed; Samreen Muzaffar; Corinne Binns; Muhammad Waqas Ilyas; Sharjeel Usmani
Journal:  Clin Nucl Med       Date:  2021-05-01       Impact factor: 7.794

2.  18F-FDG-Avid Lymph Nodes After COVID-19 Vaccination on 18F-FDG PET/CT.

Authors:  Gary A Ulaner; Peter Giuliano
Journal:  Clin Nucl Med       Date:  2021-05-01       Impact factor: 7.794

3.  Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT: A Cohort Study.

Authors:  Hanna Bernstine; Miriam Priss; Tamer Anati; Olga Turko; Miguel Gorenberg; Adam Peter Steinmetz; David Groshar
Journal:  Clin Nucl Med       Date:  2021-05-01       Impact factor: 7.794

4.  COVID Lessons Continue: Postvaccination Somatostatin Receptor-Positive Axillary Nodes on DOTATATE Imaging.

Authors:  Hina J Shah; Jason I Halpern; Gaurav V Watane; Hyewon Hyun
Journal:  Clin Nucl Med       Date:  2022-01-01       Impact factor: 7.794

5.  PET findings after COVID-19 vaccination: "Keep Calm and Carry On".

Authors:  Barbara Muoio; Luigia Elzi; Giorgio Treglia; Marco Cuzzocrea
Journal:  Clin Transl Imaging       Date:  2021-05-13

6.  Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation.

Authors:  Dan Cohen; Shir Hazut Krauthammer; Ido Wolf; Einat Even-Sapir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-27       Impact factor: 9.236

7.  Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT-not only an FDG finding.

Authors:  Ayah Adel Nawwar; Julie Searle; Rajiv Singh; Iain Douglas Lyburn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-04       Impact factor: 9.236

8.  DOTATATE -Avid Bilateral Axilla and Subpectoral Lymphadenopathy Induced From COVID-19 mRNA Vaccination Visualized on PET/CT.

Authors:  Yang Lu
Journal:  Clin Nucl Med       Date:  2021-04-01       Impact factor: 7.794

9.  The Challenge of Staging Breast Cancer With PET/CT in the Era of COVID Vaccination.

Authors:  Adam Harry Brown; Sweni Shah; Ashley M Groves; Simon Wan; Anmol Malhotra
Journal:  Clin Nucl Med       Date:  2021-04-01       Impact factor: 7.794

10.  DOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination.

Authors:  James Brophy; Gregory Henkle; Eric M Rohren
Journal:  Clin Nucl Med       Date:  2022-02-01       Impact factor: 7.794

  10 in total
  2 in total

1.  COVID-19 vaccination simulating lymph node progression in a patient with prostate cancer.

Authors:  Flavio Andresciani; Milena Ricci; Rosario Francesco Grasso; Bruno Beomonte Zobel; Carlo Cosimo Quattrocchi
Journal:  Radiol Case Rep       Date:  2022-06-17

Review 2.  COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature.

Authors:  Jihe Lim; Seun Ah Lee; Eun Kyung Khil; Sun-Ju Byeon; Hee Joon Kang; Jung-Ah Choi
Journal:  Semin Oncol       Date:  2021-10-26       Impact factor: 4.929

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.